Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 16:10:811044.
doi: 10.3389/fpubh.2022.811044. eCollection 2022.

Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019

Le Wang  1 , Bin Lu  2 , Mengjie He  3 , Youqing Wang  1 , Zongping Wang  4 , Lingbin Du  1
Affiliations

Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019

Le Wang et al. Front Public Health. .

Abstract

Aims: To evaluate current status of prostate cancer incidence and mortality worldwide, and compare the global trends of incidence and mortality in the past two decades and in the most recent period.

Methods: Data on the incidence and mortality of prostate cancer for 174 countries in 2020 were obtained from the GLOBOCAN 2020 database, and associations with the human development index (HDI) were evaluated. Data for trend analyses in 89 countries from 2000 to 2019 were retrieved from the Global Burden of Disease 2019 platform. Age standardized incidence rate (ASIR) and mortality rate (ASMR) were calculated by using the Segi's population. The average annual percent changes (AAPC) of ASIRs and ASMRs were evaluated by joinpoint regression analysis.

Results: A total of 1 414 259 new cases of prostate cancer and 375 304 related deaths were reported in 2020 globally. HDI was positively correlated with ASIRs (P < 0.001) and negatively correlated with ASMRs (P < 0.001). In the past two decades, ASIRs have been increasing in 65 countries, stable in 15 countries and decreasing in 9 countries, and ASMRs have been increasing in 19 countries, stable in 25 countries and decreasing in 45 countries, respectively. In the most recent period, 44 countries have increasing ASIRs, and 32 countries have decreasing ASMRs, respectively. For instance, in the United States of America, the AAPC of ASIRs significantly decreased by 0.62% and ASMRs significantly decreased by 1.22% from 2000 to 2019, while the AAPC from 2015 to 2019 significantly increased by 0.49% for ASIRs and significantly increased by 0.48% for ASMRs.

Conclusion: The magnitude of increasing incidence and decreasing mortality of prostate cancer is attenuated in the recent period. Further study is needed to analyze the absolute effect of risk factors, PSA screening and treatment.

Keywords: incidence; mortality; prevention; prostate cancer; screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Incidence and mortality of prostate cancer in 2020 by continent. (A) Incidence rate; (B) Mortality rate; ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate.
Figure 2
Figure 2
Correlations between age-standardized incidence and mortality of prostate cancer and human development index. (A) age-standardized incidence rate; (B) age-standardized mortality rate.
Figure 3
Figure 3
The AAPC of the ASIR (blue bars) and ASMR (red bars) of prostate cancer. *P < 0.05. AAPC, Average annual percent change; ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate.
Figure 4
Figure 4
Comparisons of changing trends in most recent period with that in full period.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. (2021) 71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. (2020) 77:38–52. 10.1016/j.eururo.2019.08.005 - DOI - PubMed
    1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol. (2012) 61:1079–92. 10.1016/j.eururo.2012.02.054 - DOI - PubMed
    1. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. (2013) 63:800–9. 10.1016/j.eururo.2012.11.013 - DOI - PMC - PubMed
    1. Reiter-Brennan C, Dzaye O, Al-Mallah MH, Dardari Z, Brawner CA, Lamerato LE, et al. . Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project. Cancer. (2021) 127:1864–70. 10.1002/cncr.33426 - DOI - PubMed

Publication types